<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25515" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nalbuphine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Larsen</surname>
            <given-names>Devin</given-names>
          </name>
          <aff>San Antonio Military Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Maani</surname>
            <given-names>Christopher V.</given-names>
          </name>
          <aff>US Army; USUHS; BAMC; UTHSCSA; UIW</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Devin Larsen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christopher Maani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25515.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Nalbuphine is FDA indicated for moderate to severe pain in which an opioid agent is required when other alternative treatments have been insufficient. Non-FDA approved uses of nalbuphine do exist, such as treatment of labor pain, opioid-induced urinary retention, opioid-induced respiratory depression, and pruritus associated with neuraxial opioid use. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, monitoring, and toxicity of nalbuphine, so providers can direct patient therapy to optimal outcomes when pain relief is needed.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action nalbuphine.</p></list-item><list-item><p>Outline the approved and off-label indications for using nalbuphine.</p></list-item><list-item><p>Review the potential adverse effect profile of nalbuphine.</p></list-item><list-item><p>Summarize the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who can benefit from therapy with nalbuphine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25515&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25515">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25515.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Nalbuphine is FDA indicated for moderate to severe pain in where the patient requires an opioid agent, and other alternative treatments have been insufficient. Non-FDA approved uses of nalbuphine do&#x000a0;exist such as treatment of labor pain, opioid-induced urinary retention, opioid-induced respiratory depression, and pruritus associated with neuraxial opioid use.</p>
        <p>Pruritus is usually secondary to opioid activation of the mu-opioid receptor. Because nalbuphine is an antagonist at the mu-opioid receptor, it has utility as a treatment for opioid-induced pruritus. In fact, research has found that nalbuphine to be&#x000a0;superior in treating opioid-induced pruritus when compared with placebo, diphenhydramine, naloxone, or propofol in patients receiving neuraxial opioids for acute pain related to surgery or childbirth1.<xref ref-type="bibr" rid="article-25515.r1">[1]</xref></p>
        <p>Although nalbuphine can result in respiratory depression, due to its antagonism of the mu-opioid receptor, it antagonizes the respiratory depressant effects of other opioid medications while concomitantly adding to the analgesic activities of these drugs.<xref ref-type="bibr" rid="article-25515.r2">[2]</xref>&#x000a0;When used acutely in the perioperative period, nalbuphine is useful for providing analgesic benefits with less respiratory depression than morphine. In one study, researchers used intravenous nalbuphine to reduce opioid-induced respiratory suppression following intrathecal morphine administration in post-thoracotomy patients.<xref ref-type="bibr" rid="article-25515.r3">[3]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25515.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Nalbuphine is a&#x000a0;kappa-opioid receptor agonist and a partial mu-opioid receptor antagonist. Analgesic properties are mediated through agonist activity at the&#x000a0;kappa-opioid receptor. Because of this unique mixed agonist-antagonist opioid receptor activity of nalbuphine, it provides analgesia with less nausea, pruritus, and respiratory depression when compared to morphine.<xref ref-type="bibr" rid="article-25515.r4">[4]</xref></p>
        <p>
<bold>Pharmacology</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Absorption</bold>: The onset of action of nalbuphine after intravenous injection is 2 to 3 minutes. With subcutaneous or intramuscular administration, the onset of action is within 15 minutes. The duration of action of nalbuphine ranges from 3 to 6 hours.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Distribution</bold>: Protein binding not significant.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Metabolism</bold>: Nalbuphine is hepatically metabolized.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Elimination</bold>: Elimination half-life of about 5 hours. Excreted in urine and feces.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25515.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Nalbuphine is available in 10 mg/ml and 20 mg/ml injectable solutions. Nalbuphine is not available in oral form secondary to poor oral bioavailability.<xref ref-type="bibr" rid="article-25515.r5">[5]</xref></p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>A typical recommended dose is 10 mg for a 70 kg individual. The administration is subcutaneous, intramuscular, or intravenous; this dose may be repeated every 3 to 6 hours as necessary. The recommended single maximum dose is 20mg in an opioid, nontolerant individual with a maximum daily dose of 160mg. In opioid-dependent patients, the dose should be reduced by&#x000a0;25%, and the patient should be observed for signs of opioid withdrawal. In patients who are not opioid-tolerant, withdrawal symptoms have not been seen&#x000a0;from other opioid medications that have been given in the same acute setting as nalbuphine. The potency of nalbuphine is comparable to morphine on a mg-to-mg basis.<xref ref-type="bibr" rid="article-25515.r6">[6]</xref></p>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <p>Less than one year: safety and efficacy not established.</p>
        <p>Greater than one year: 0.1&#x000a0;to 0.2 mg/kg intravenously, intramuscularly, or subcutaneously every 3&#x000a0;to 4 hours as needed. The maximum single dose is 20 mg. Maximum daily dose 160 mg.</p>
        <p>Renal impairment: use caution, may require a reduced dose.</p>
        <p>Hepatic impairment: use caution, may require a reduced dose.</p>
      </sec>
      <sec id="article-25515.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effects following nalbuphine administration are sedation, sweating, nausea, vomiting, dizziness, vertigo, dry mouth, or a headache.<xref ref-type="bibr" rid="article-25515.r7">[7]</xref><xref ref-type="bibr" rid="article-25515.r8">[8]</xref></p>
        <p>The following are less common adverse effects that have been reported at an incidence of less than 1%:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Central nervous system</bold>: Nervousness, depression, restlessness, crying, euphoria, floating, hostility, unusual dreams, confusion, faintness, hallucinations, dysphoria, a feeling of heaviness, numbness, tingling, or unreality.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cardiovascular</bold>: hypertension, hypotension, bradycardia, or tachycardia.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Gastrointestinal</bold>: cramps, dyspepsia, or bitter taste.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Respiratory</bold>: depression, dyspnea, or asthma.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Dermatologic</bold>: itching, burning, or urticaria.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Allergic Reactions</bold>: anaphylactic, anaphylactoid, or severe hypersensitivity reactions have been reported with nalbuphine use, and care should be given providing immediate supportive medical treatment should they occur.</p>
          </list-item>
        </list>
        <p>
<bold>Black Box Warning</bold>
</p>
        <p>Concomitant use of nalbuphine with benzodiazepines or other CNS depressants, including alcohol, may result in critical sedation, respiratory depression, coma, and death.</p>
        <p>Concomitant prescribing should only be used in&#x000a0;patients for whom alternative treatment options have proved inadequate; dose and duration should be limited to the minimum required, and follow patients for signs and symptoms of respiratory depression and sedation.</p>
        <p>
<bold>Cautions</bold>
</p>
        <p>Because of altered pharmacokinetics and clearance in elderly, debilitated, or cachectic patients, caution should be used when administering nalbuphine to these patient populations because life-threatening respiratory depression can result. The respiratory depressant effects of nalbuphine can result in carbon dioxide retention, which can further increase intracranial pressure in patients with baseline elevated intracranial pressure, head injury, or intracranial lesions, as well as possibly confound the ability to obtain and follow an accurate neurological examination due to sedative properties. Therefore, nalbuphine should be used with extreme in these clinical scenarios.</p>
        <p>Like other commonly used opioid medications, nalbuphine can alter normal mental or physical abilities required to perform potentially dangerous tasks, including driving or operating heavy machinery. Patients counseling regarding these risks prior to&#x000a0;the administration of this medication is&#x000a0;indicated.</p>
        <p>Nalbuphine has been used for obstetrical analgesia, and there are reports of severe fetal bradycardia in laboring women. In one study, fetal heart rate flattening occurred in 53% of the cases.<xref ref-type="bibr" rid="article-25515.r9">[9]</xref> The benefits of analgesia versus risks to the fetus should be weighed in this clinical situation. If nalbuphine is administered to the laboring woman, fetal heart rate monitoring should be utilized, and appropriate&#x000a0;procedures in place to manage any adverse effects to the fetus. Naloxone may reverse these effects.</p>
        <p>Due to antagonist action at the &#x000b5;-opioid receptor, caution should be used in nalbuphine administration to patients on sustained-release opioids because withdrawal symptoms are possible.<xref ref-type="bibr" rid="article-25515.r4">[4]</xref> When using nalbuphine in these patients, reduced dosing is advised, and the patient should be observed for signs of withdrawal.</p>
        <p>Even though nalbuphine is a &#x000b5;-opioid receptor antagonist, it still provides drug liking properties and has abuse potential.<xref ref-type="bibr" rid="article-25515.r4">[4]</xref>&#x000a0;Of note, naloxone was initially classified as a scheduled II controlled substance, however through subsequent petitioning to the FDA by its manufacturer, it was removed from all schedules and is no longer a controlled substance in the U.S.</p>
      </sec>
      <sec id="article-25515.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Nalbuphine is contraindicated in patients with:</p>
        <list list-type="bullet">
          <list-item>
            <p>Significant respiratory depression</p>
          </list-item>
          <list-item>
            <p>Severe or active bronchial asthma</p>
          </list-item>
          <list-item>
            <p>Known or suspected gastrointestinal obstruction, including ileus</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to nalbuphine or any other ingredients in the injection</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25515.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Significant respiratory depression can occur with nalbuphine at any time, although it is most common after initiation of the medication or increase in dosage. Patients should undergo close monitoring for the first 24-72 hours after initiating therapy or increasing dosage.</p>
      </sec>
      <sec id="article-25515.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In cases of overdose or adverse reactions, intravenous naloxone administration is the antidote.<xref ref-type="bibr" rid="article-25515.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25515.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The use of nalbuphine and other potent opioid medications requires an interprofessional team approach to patient management involving physicians, nurses, and pharmacists to ensure patient safety, beginning&#x000a0;with medication ordering, preparation, administration, and patient monitoring following administration of the drug. Although nalbuphine is not classified as a controlled substance under the controlled substances act, it is still a prescription medication, and caution should be undertaken with its use. The responsibility falls on all healthcare professionals on the healthcare team to inform patients of possible increased risk associated with opioid medications in an effort&#x000a0;to protect patients from the dangerous adverse effects of this class of medications.<xref ref-type="bibr" rid="article-25515.r10">[10]</xref><xref ref-type="bibr" rid="article-25515.r4">[4]</xref><xref ref-type="bibr" rid="article-25515.r11">[11]</xref>&#x000a0;This type of interprofessional teamwork will result in better therapeutic outcomes with fewer adverse reactions for patients on nalbuphine therapy. [Level 5]</p>
      </sec>
      <sec id="article-25515.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25515&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25515">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25515/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25515">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25515.s11">
        <title>References</title>
        <ref id="article-25515.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jannuzzi</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature.</article-title>
            <source>Clin J Pain</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-93</page-range>
            <pub-id pub-id-type="pmid">26650717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25515.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Shotzberger</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vernier</surname>
                <given-names>VG</given-names>
              </name>
            </person-group>
            <article-title>Nalbuphine.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>1985</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>3-4</issue>
            <fpage>339</fpage>
            <page-range>339-62</page-range>
            <pub-id pub-id-type="pmid">2986929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25515.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baxter</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Samson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Penning</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Doran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dube</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Prevention of epidural morphine-induced respiratory depression with intravenous nalbuphine infusion in post-thoracotomy patients.</article-title>
            <source>Can J Anaesth</source>
            <year>1989</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>503</fpage>
            <page-range>503-9</page-range>
            <pub-id pub-id-type="pmid">2507181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25515.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Regel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Does nalbuphine have a niche in managing pain?</article-title>
            <source>J Opioid Manag</source>
            <year>2018</year>
            <season>Mar/Apr</season>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-151</page-range>
            <pub-id pub-id-type="pmid">29733100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25515.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Behm</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>What Parenteral Opioids to Use in Face of Shortages of Morphine, Hydromorphone, and Fentanyl.</article-title>
            <source>Am J Hosp Palliat Care</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1118</fpage>
            <page-range>1118-1122</page-range>
            <pub-id pub-id-type="pmid">29649890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25515.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Errick</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Heel</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy.</article-title>
            <source>Drugs</source>
            <year>1983</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>191</fpage>
            <page-range>191-211</page-range>
            <pub-id pub-id-type="pmid">6137354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25515.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chr&#x000e9;tien</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dolladille</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hamel-S&#x000e9;n&#x000e9;cal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sassier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faillie</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Miremont-Salam&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lelong-Boulouard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Le Boisselier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fedrizzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alexandre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Comparative study of hypoglycaemia induced by opioids. Is it a class effect?</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>987</fpage>
            <page-range>987-992</page-range>
            <pub-id pub-id-type="pmid">31317815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25515.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dinges</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stay</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>B&#x000e4;umlein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Waldmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kranke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wulf</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Eberhart</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Side Effect Rates of Opioids in Equianalgesic Doses via Intravenous Patient-Controlled Analgesia: A Systematic Review and Network Meta-analysis.</article-title>
            <source>Anesth Analg</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>129</volume>
            <issue>4</issue>
            <fpage>1153</fpage>
            <page-range>1153-1162</page-range>
            <pub-id pub-id-type="pmid">30418234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25515.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicolle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Devillier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Delanoy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Durand</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bessard</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic monitoring of nalbuphine: transplacental transfer and estimated pharmacokinetics in the neonate.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1996</year>
            <volume>49</volume>
            <issue>6</issue>
            <fpage>485</fpage>
            <page-range>485-9</page-range>
            <pub-id pub-id-type="pmid">8706774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25515.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pisanu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Franconi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gessa</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Mameli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pisanu</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Campesi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Leggio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Agabio</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sex differences in the response to opioids for pain relief: A systematic review and meta-analysis.</article-title>
            <source>Pharmacol Res</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>148</volume>
            <fpage>104447</fpage>
            <pub-id pub-id-type="pmid">31499196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25515.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <article-title>Opioids for pain.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2018</year>
            <month>Apr</month>
            <day>09</day>
            <volume>60</volume>
            <issue>1544</issue>
            <fpage>57</fpage>
            <page-range>57-64</page-range>
            <pub-id pub-id-type="pmid">29664446</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
